Aptis to Participate in World ADC... Showcasing the Excellence of 'AbClick'

To Be Held in San Diego on October 3
Oral Presentation on the Excellence of AbClick

Aptis announced on October 28 that it will participate in World ADC 2025, which will be held in San Diego, USA, from November 3 to 6 (local time), to promote its AbClick® platform.

At last year's World ADC 2024 event, Tae Dong Han, CEO of Aptis, is giving a presentation. Aptis

The World ADC series is regarded as the premier event in the antibody-drug conjugate (ADC) field. Approximately 750 ADC experts attend, with poster presentation sessions, exhibition booths, and partnering opportunities facilitating active business meetings and information sharing within the ADC sector.

Following last year, Aptis plans to operate a booth again this year to create a variety of business opportunities.

In particular, Aptis will introduce the differentiated technological advantages of its third-generation ADC linker technology, AbClick®, to attendees through an oral presentation. AbClick® enables selective drug conjugation at specific sites on the antibody Fc domain, does not require the production of mutant antibodies, and ensures a uniform drug-to-antibody ratio (DAR) of consistent quality.

The title of the presentation is "Harnessing the site-selective conjugation platform AbClick® for innovative bioconjugate therapies."

Tae Dong Han, CEO of Aptis, stated, "We will deliver both an oral presentation and a poster presentation on the technical excellence and scalability of AbClick®. Through this conference, we aim to strengthen our global ADC business network and further expand collaborations with global companies based on Aptis’s competitiveness."

Meanwhile, CEO Tae Dong Han, Executive Vice President Jung Sangjeon, Research Director Pyo Kyungho, and other key staff members are scheduled to attend World ADC 2025.

This content was produced with the assistance of AI translation services.